References:
1.-Cornec D, Cornec-Le Gall E, Fervenza F, Specks U. ANCA-associated
vasculitis - clinical utility of using ANCA specificity to classify
patients. Nat Rev Rheumatol 2016;12:570-579.
2.-Bossuyt X, Cohen Tervaert JW, Arimura Y, Blockmans D, Flores-Suárez
LF, Guillevin L et al. Revised 2017 international consensus on testing
of ANCAs in granulomatosis with polyangiitis and microscopic
polyangiitis. Nature Rev Rheumatol 2017;13:683-692.
3.-Birck R, Schmitt WH, Kaelsch IA, van der Woude FJ. Serial ANCA
Determinations for monitoring disease activity in patients with
ANCA-associated vasculitis: systematic review. Am J Kidney Dis
2005;47:15-23.
4.-Kerr GS, Fleisher TA, Hallahan CW, Leavitt RY, Fauci AS, Hoffman GS.
Limited prognostic value of changes in antineutrophil cytoplasmic
antibody titer in patients with Wegener’s granulomatosis. Arthritis
Rheum 1993;36:365-371.
5.-Davenport A, Lock RJ, Wallington T. Clinical significance of the
serial measurement of autoantibodies to neutrophil cytoplasm using a
standard indirect immunofluorescence test. Am J Nephrol
1995;15:201–207.
6.-Finkielman JD, Lee AS, Hummel AM, Viss MA, Jacob GL, Homburger HA, et
al. ANCA are detectable in nearly all patients with active severe
Wegener’s granulomatosis. Am J Med 2007;120:643.e9–643.e14.
7.-Verstockt B, Bossuyt X, Vanderschueren S, Blockmans D. There is no
benefit in routinely monitoring ANCA titers in patients with
granulomatosis with polyangiitis. Clin Exp Rheumatol 2015; 33: S72-S76.
8.-Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP, et
al. The American College of Rheumatology 1990 criteria for the
classification of Wegener’s granulomatosis. Arthritis Rheum
1990;33:1101-1107.
9.-Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, et al. The
American college of rheumatology 1990 criteria for the classification of
Churg-Strauss syndrome. Arthritis Rheum 1990;33:1094-1100.
10.-Kyndt X, Reumaux D, Bridoux F, et al. Serial Measurements of
Antineutrophil cytoplasmic autoantibodies in patients with systemic
vasculitis. Am J Med. 1999;106:527–533.
11.-Lionaki S, Blyth ER, Hogan SL, Hu Y, Senior BA, Jennette CE et al.
Classification of antineutrophil cytoplasmic autoantibody vasculitides:
the role of antineutrophil cytoplasmic autoantibody specificity for
myeloperoxidase or proteinase 3 in disease recognition and prognosis.
Arthritis Rheum 2012;64:3452-3462.
12.-Terrier B, Saadoun D, Sène D, Ghillani P, Amoura Z, Deray G et al.
Antimyeloperoxidase antibodies are a useful marker of disease activity
in antineutrophil cytoplasmic antibody-associated vasculitides. Ann
Rheum Dis 2009;68:1564–1571.
13.-Tomasson G, Grayson PC, Mahr AD, LaValley M, Merkel PA. Value of
ANCA measurements during remission to predict a relapse of
ANCA-associated vasculitis—a meta-analysis. Rheumatology 2012; 51:
100-109.
14.-Kemna MJ, Damoiseaux J, Austen J, et al. ANCA as a predictor of
relapse: useful in patients with renal involvement but not in patients
with nonrenal disease. J Am Soc Nephrol 2015;26:537–542.
15.-Robson J, Doll H, Suppiah R, Flossmann O, Harper L, Höglund P et al.
Damage in the ANCA-associated vasculitides: long-term data from the
European Vasculitis Study group (EUVAS) therapeutic trials. Ann Rheum
Dis 2015;74: 177–184.
16.-Tanna A, Guarino L, Tam FWK, Rodriquez-Cubillo B, Levy JB, Cairns TD
et al. Long-term outcome of anti-neutrophil cytoplasm
antibody-associated glomerulonephritis: evaluation of the international
histological classification and other prognostic factors. Nephrol Dial
Transplant 2015;30:1185–1192.
17.-Mohammad AJ, Segelmark M. A population-based study showing better
renal prognosis for proteinase 3 antineutrophil cytoplasmic antibody
(ANCA)-associated nephritis versus myeloperoxidase ANCA-associated
nephritis. J. Rheumatol 2014;41:1366–1373
18.-Vizjak A, Rott T, Koselj-Kajtna M, Rozman B, Kaplan-Pavlovcic S,
Ferluga D. Histologic and immunohistologic study and clinical
presentation of ANCA-associated glomerulonephritis with correlation to
ANCA antigen specificity. Am J Kidney Dis 2003;41:539-549.
19.-de Joode AAE, Sanders J SF, Stegeman CA. Renal survival in
proteinase 3 and myeloperoxidase ANCA-associated systemic vasculitis.
Clin J Am Soc Nephrol 2013; 8:1709-1717.
20.-Quintana LF, Perez NS, De Sousa E, Rodas LM, Griffiths MH, Solé M et
al. ANCA serotype and histopathological classification for the
prediction of renal outcome in ANCAassociated glomerulonephritis.
Nephrol Dial Transplant 2014; 29:1764-1769.
21.-Sada KE, Yamamura M, Harigai M, Fujii T, Takasaki Y, Amano K, et al.
Different responses to treatment across classified diseases and
severities in Japanese patients with microscopic polyangiitis and
granulomatosis with polyangiitis: a nationwide prospective inception
cohort study. Arthritis Res Ther 2015; 17: 305.
22.-Franssen CFM, Gans ROB, Arends AJ, Hageluken C, ter Wee PM, Gerlag
PGG et al. Differences between anti-myeloperoxidase-and anti-proteinase
3 associated renal disease. Kidney Int 1995; 47:193–199.
23.-Westman KW, Bygren PG, Olsson H, Ranstam J, Wieslander J. Relapse
rate, renal survival, and cancer morbidity in patients with Wegener’s
granulomatosis or microscopic polyangiitis with renal involvement. J Am
Soc Nephrol 1998;9:842-852.
24.-Marco H, Draibe, Villacorta J, Quintana LF, Martin N, Garcia-Osuna N
et al. Determinants of renal and patient outcomes in a Spanish cohort of
patients with ANCA-associated vasculitis and renal involvement. Clinical
Rheumatology. doi.org/10.1007/s10067-017-3973-3982.
25.-Guilpain P, Chereau C, Goulvestre C, Servettaz A, Montani D, Tamas N
et al. The oxidation induced by antimyeloperoxidase antibodies triggers
fibrosis in microscopic polyangiitis. Eur Respir J 2011; 37: 1503–1513
26.Tzelepis GE, Kokosi M, Tzioufas A, Toya SP, Boki KA, Zormpala A et
al. Prevalence and outcome of pulmonary fibrosis in microscopic
polyangiitis. Eur Respiratory J 2010 36: 116-121.
27.-Comarmond C, Crestani B, Tazi A, Hervier B, Adam-Marchand S, Nunes H
et al. Pulmonary fibrosis in antineutrophil cytoplasmic antibodies
(ANCA)- associated vasculitis: a series of 49 patients and review of the
literature. Medicine (Baltimore) 2014;93:340–349.
28.-Franssen CFM, Stegeman CA, Oost-Kort WW, Kallenberg CGM, Limburg PC,
Tiebosch A et al. Determinants of renal outcome in
anti-myeloperoxidase-associated necrotizing crescentic
glomerulonephritis. J Am Soc Nephrol 1998;9:1915-1923.
Table 1. Clinical characteristics and outcome of ANCA-associated
vasculitis according to antigenic specificity.
Table 2. Clinical characteristics and outcome of ANCA-associated
vasculitis according to ANCA pattern
Table 3. Variables associated with clinical relapses in GPA amd MPA
Table 4. Variables associated with clinical relapses in GPA and MPA.
Multivariate analysis.
Table 5. Variables associated with worsening renal failure in anti-MPO
vasculitis. Univariate analysis.
Table 6. Variables associated with worsening renal failure in anti-MPO
vasculitis. Multivariate analysis
Fig 1. Clinical relapse according to ANCA pattern in GPA and MPA. A: all
ANCA vasculitis; B: anti-PR3 vasculitis; C: anti-MPO vasculitis.
Fig 2. Worsening renal failure according to ANCA pattern in GPA or MPA
anti-MPO vasculitis.